A Phase 2 interventional study of Ropanicant in Major Depressive Disorder, sponsored by Suven Life Sciences Limited. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Suven Life Sciences Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 838th largest by enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2024, is one of 271 in phase 2, and was the 1,288th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 70 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Suven Life Sciences Limited has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Approximately 36 participants will be randomly assigned to receive Ropanicant either Ropanicant 45 mg once a day (QD), Ropanicant 30 mg twice a day (BID), or Ropanicant 45 mg BID for 2 weeks, in a ratio of 1:1:1 (12 participants in each treatment group). Following a screening period of up to 4 weeks, the participants will be treated for 2 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participant will take 1 tablet/day in the morning (for qd dosing)
Drug: Ropanicant
The participant will take 2 tablets/day (\~12 hours apart for bid dosing).
Drug: Ropanicant
The participant will take 2 tablets/day (\~12 hours apart for bid dosing).
Drug: Ropanicant
Tablet
Also known as: SUVN-911
Number of Participants With Treatment-Emergent Adverse Events
Participants with at least one Treatment-emergent adverse events (TEAEs) reported during the duration of the study.
Time frame: From Screening to Day 21
Montgomery-Åsberg Depression Rating Scale (MADRS) Score
Change from the baseline to the MADRS total score. The MADRS is a clinician-rated scale to assess depressive symptoms which consists of 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.
Time frame: From Baseline to Day 14
| Milestone | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID |
|---|---|---|---|
| Started | 14 | 14 | 13 |
| Completed | 12 | 12 | 13 |
| Not completed | 2 | 2 | 0 |
Participants with at least one Treatment-emergent adverse events (TEAEs) reported during the duration of the study.
| Participants | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 6 | 6 | 6 |
Change from the baseline to the MADRS total score. The MADRS is a clinician-rated scale to assess depressive symptoms which consists of 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.
| score on a scale | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID |
|---|---|---|---|
| Montgomery-Åsberg Depression Rating Scale (MADRS) Score | -10.5 ± 7.47 | -12.7 ± 9.54 | -10.4 ± 6.51 |
Collected over From Screening to Day 21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ropanicant 45 mg, QD | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Ropanicant 30 mg, BID | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Ropanicant 45 mg, BID | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Event | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID |
|---|---|---|---|
| Sucidal ideationPsychiatric disorders | 1/14 | 2/13 | 1/13 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/13 | 2/13 |
| SomnolenceGastrointestinal disorders | 0/14 | 2/13 | 0/13 |
| InsomniaPsychiatric disorders | 1/14 | 0/13 | 1/13 |
| NauseaGastrointestinal disorders | 1/14 | 1/13 | 1/13 |
| HeadacheNervous system disorders | 1/14 | 1/13 | 0/13 |
| Blood creatine phosphokinase increasedInvestigations | 1/14 | 0/13 | 1/13 |
| FatigueGeneral disorders | 0/14 | 1/13 | 1/13 |
| PollakiuriaRenal and urinary disorders | 1/14 | 1/13 | 0/13 |
| Hallucination, visualPsychiatric disorders | 0/14 | 0/13 | 1/13 |
The Baseline analysis population considered is Safety Set which included all participants who received any study drug.
| Age, Categorical(Participants) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 13 | 13 | 40 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| Mean | 42.8 ± 13.74 | 39.5 ± 13.28 | 52.5 ± 11.28 | 44.9 ± 13.67 |
| Sex: Female, Male(Participants) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| Female | 10 | 9 | 9 | 28 |
| Male | 4 | 4 | 4 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 | 4 |
| Not Hispanic or Latino | 12 | 13 | 11 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 6 | 8 | 21 |
| White | 7 | 6 | 5 | 18 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| United States | 14 | 13 | 13 | 40 |
| Montgomery-Asberg Depression Rating Scale (MADRS)(units on a scale) | Ropanicant 45 mg, QD | Ropanicant 30 mg, BID | Ropanicant 45 mg, BID | Total |
|---|---|---|---|---|
| Mean | 31.7 ± 3.50 | 33.6 ± 6.27 | 31.0 ± 3.42 | 32.1 ± 4.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2024 to primary completion in Jul 2024, 5 months.
Results were first posted in Sep 2026, 2 years 1 month after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 5 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suven Life Sciences Limited